Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy? Yahoo Finance
Covered in this story
What has happened since
- Biogen is down 0.2% since this was published.
- Amgen is down 1.1% since this was published.
- Gilead Sciences is down 1.7% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Biogen
- BMO Capital Markets: $229 → $220 by Oct 2027 · Market Perform via Investing.com
- Wolfe Research: $216 → $300 by Sep 2027 · Outperform via Yahoo Finance
- H.C. Wainwright: $203 → $251 by Jul 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BIIB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Biogen →Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.